Women who are prescribed opioids after childbirth have an increased risk of persistent opioid use or other serious opioid-related events, including overdose, in their first year postpartum, according to a new study by Vanderbilt University Medical Center researchers. This is true regardless of whether the woman had a vaginal delivery or a cesarean section.

Out of concern for fetal safety, pregnant people have typically been excluded from drug trials. And when human health is on the line, drug studies assessing fetal safety in animal models may be viewed as far from definitive.

Pregnant women involved in the criminal justice system are disproportionately not receiving medications for opioid use disorder, as compared to their peers, according to a Vanderbilt-led study published today in PLOS Medicine.

The novel coronavirus, known as COVID-19, is raising concern about the impact of the illness on pregnant women.

To provide additional maternity care and a full spectrum of birthing experience options for patients, Vanderbilt University Medical Center has announced plans to acquire the Nashville location of Baby+Company, a freestanding birthing center that emphasizes a family-centered, low-intervention approach to delivery for uncomplicated pregnancies.

Hearing that she could deliver her second child with no out-of-pocket expense convinced Vanderbilt University Medical Center employee Amy New to enroll in the new MyMaternityHealth Bundle offered by Vanderbilt Health, and she quickly learned the program’s advantages didn’t stop there.

The Vanderbilt Maternal Addiction Recovery Program is participating in a 12-site clinical trial that will compare two forms of the medication buprenorphine in treating opioid use disorder during pregnancy, and the results could have a potentially significant impact on clinical practice.